Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Current Assets (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Current Assets data on record, last reported at $44.4 million in Q3 2025.

  • For Q3 2025, Current Assets fell 7.09% year-over-year to $44.4 million; the TTM value through Sep 2025 reached $44.4 million, down 7.09%, while the annual FY2024 figure was $37.4 million, 48.17% down from the prior year.
  • Current Assets reached $44.4 million in Q3 2025 per BTAI's latest filing, up from $25.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $244.9 million in Q2 2022 and bottomed at $25.2 million in Q2 2025.
  • Average Current Assets over 4 years is $114.7 million, with a median of $80.9 million recorded in 2024.
  • Peak YoY movement for Current Assets: tumbled 64.44% in 2023, then dropped 7.09% in 2025.
  • A 4-year view of Current Assets shows it stood at $202.9 million in 2022, then crashed by 64.44% to $72.1 million in 2023, then plummeted by 48.17% to $37.4 million in 2024, then rose by 18.74% to $44.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $44.4 million in Q3 2025, $25.2 million in Q2 2025, and $37.8 million in Q1 2025.